Business Description
Medigen Biotechnology Corp
NAICS : 325412
SIC : 2834
ISIN : TW0003176004
Compare
Compare
Traded in other countries / regions
3176.Taiwan IPO Date
2011-11-23Description
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.42 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | -2.11 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.13 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.3 | |||||
| 3-Year EBITDA Growth Rate | -18.3 | |||||
| 3-Year EPS without NRI Growth Rate | -17.2 | |||||
| 3-Year FCF Growth Rate | 13.1 | |||||
| 3-Year Book Growth Rate | -4.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.47 | |||||
| 9-Day RSI | 43.39 | |||||
| 14-Day RSI | 40.78 | |||||
| 6-1 Month Momentum % | -12.57 | |||||
| 12-1 Month Momentum % | -32.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.07 | |||||
| Quick Ratio | 3.38 | |||||
| Cash Ratio | 2.76 | |||||
| Days Inventory | 404.34 | |||||
| Days Sales Outstanding | 54.84 | |||||
| Days Payable | 38.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 17.86 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.86 | |||||
| Operating Margin % | -49.63 | |||||
| Net Margin % | -29.22 | |||||
| FCF Margin % | -12.44 | |||||
| ROE % | -24.68 | |||||
| ROA % | -5.22 | |||||
| ROIC % | -18.74 | |||||
| ROC (Joel Greenblatt) % | -26.6 | |||||
| ROCE % | -11.25 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 94.46 | |||||
| PS Ratio | 3.52 | |||||
| PB Ratio | 2.9 | |||||
| Price-to-Tangible-Book | 3.08 | |||||
| EV-to-EBIT | -5.13 | |||||
| EV-to-EBITDA | -6.98 | |||||
| EV-to-Revenue | 2.41 | |||||
| EV-to-FCF | -19.4 | |||||
| Price-to-Median-PS-Value | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -19.5 | |||||
| FCF Yield % | -3.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigen Biotechnology Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,413.084 | ||
| EPS (TTM) (NT$) | -2.964 | ||
| Beta | 0.65 | ||
| Volatility % | 62.07 | ||
| 14-Day RSI | 40.78 | ||
| 14-Day ATR (NT$) | 0.818064 | ||
| 20-Day SMA (NT$) | 35.505 | ||
| 12-1 Month Momentum % | -32.01 | ||
| 52-Week Range (NT$) | 33.6 - 54 | ||
| Shares Outstanding (Mil) | 139.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigen Biotechnology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigen Biotechnology Corp Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medigen Biotechnology Corp Frequently Asked Questions
What is Medigen Biotechnology Corp(ROCO:3176)'s stock price today?
The current price of ROCO:3176 is NT$34.90. The 52 week high of ROCO:3176 is NT$54.00 and 52 week low is NT$33.60.
When is next earnings date of Medigen Biotechnology Corp(ROCO:3176)?
The next earnings date of Medigen Biotechnology Corp(ROCO:3176) is .
Does Medigen Biotechnology Corp(ROCO:3176) pay dividends? If so, how much?
Medigen Biotechnology Corp(ROCO:3176) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers